COCRYSTAL PHARMA NEW O.N. (8CC) - Total Assets
Based on the latest financial reports, COCRYSTAL PHARMA NEW O.N. (8CC) holds total assets worth €9.71 Million EUR (≈ $11.35 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 8CC net asset value for net asset value and shareholders' equity analysis.
COCRYSTAL PHARMA NEW O.N. - Total Assets Trend (2021–2025)
This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s total assets have evolved over time, based on quarterly financial data.
COCRYSTAL PHARMA NEW O.N. - Asset Composition Analysis
Current Asset Composition (December 2025)
COCRYSTAL PHARMA NEW O.N.'s total assets of €9.71 Million consist of 83.8% current assets and 16.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 72.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of COCRYSTAL PHARMA NEW O.N..
Key Asset Composition Facts
- Current vs. Non-Current Assets: COCRYSTAL PHARMA NEW O.N.'s current assets represent 83.8% of total assets in 2025, an increase from 74.7% in 2021.
- Cash Position: Cash and equivalents constituted 72.3% of total assets in 2025, down from 73.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 24.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
COCRYSTAL PHARMA NEW O.N. Competitors by Total Assets
Key competitors of COCRYSTAL PHARMA NEW O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Crispr Therapeutics AG
NASDAQ:CRSP
|
USA | $2.73 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
COCRYSTAL PHARMA NEW O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.68 | 4.77 | 7.32 |
| Quick Ratio | 3.68 | 4.77 | 7.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.92 Million | €9.15 Million | €12.31 Million |
COCRYSTAL PHARMA NEW O.N. - Advanced Valuation Insights
This section examines the relationship between COCRYSTAL PHARMA NEW O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 1.57 |
| Asset Growth Rate (YoY) | -27.8% |
| Total Assets | €9.71 Million |
| Market Capitalization | $15.23 Million USD |
Valuation Analysis
Above Book Valuation: The market values COCRYSTAL PHARMA NEW O.N.'s assets above their book value (1.57x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: COCRYSTAL PHARMA NEW O.N.'s assets decreased by 27.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for COCRYSTAL PHARMA NEW O.N. (2021–2025)
The table below shows the annual total assets of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €9.71 Million ≈ $11.35 Million |
-27.82% |
| 2024-12-31 | €13.46 Million ≈ $15.73 Million |
-56.95% |
| 2023-12-31 | €31.26 Million ≈ $36.55 Million |
-23.46% |
| 2022-12-31 | €40.84 Million ≈ $47.75 Million |
-48.56% |
| 2021-12-31 | €79.39 Million ≈ $92.82 Million |
-- |
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more